Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001104659-26-027052
Filing Date
2026-03-12
Accepted
2026-03-12 16:06:12
Documents
74
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K acxp-20251231x10k.htm   iXBRL 10-K 2423629
2 EX-4.11 acxp-20251231xex4d11.htm EX-4.11 33153
3 EX-21.1 acxp-20251231xex21d1.htm EX-21.1 1241
4 EX-23.1 acxp-20251231xex23d1.htm EX-23.1 4091
5 EX-31.1 acxp-20251231xex31d1.htm EX-31.1 10646
6 EX-31.2 acxp-20251231xex31d2.htm EX-31.2 10581
7 EX-32.1 acxp-20251231xex32d1.htm EX-32.1 4600
8 EX-32.2 acxp-20251231xex32d2.htm EX-32.2 4645
9 GRAPHIC acxp-20251231x10k002.jpg GRAPHIC 40256
10 GRAPHIC acxp-20251231x10k003.jpg GRAPHIC 15929
11 GRAPHIC acxp-20251231x10k004.jpg GRAPHIC 83834
12 GRAPHIC acxp-20251231x10k006.jpg GRAPHIC 22880
13 GRAPHIC acxp-20251231x10k007.jpg GRAPHIC 17202
14 GRAPHIC acxp-20251231x10k008.jpg GRAPHIC 7363
15 GRAPHIC acxp-20251231x10k009.jpg GRAPHIC 32289
16 GRAPHIC acxp-20251231x10k011.jpg GRAPHIC 63354
17 GRAPHIC acxp-20251231x10k012.jpg GRAPHIC 92134
18 GRAPHIC acxp-20251231x10k013.jpg GRAPHIC 121972
19 GRAPHIC acxp-20251231x10k014.jpg GRAPHIC 49687
20 GRAPHIC acxp-20251231x10k015.jpg GRAPHIC 23100
  Complete submission text file 0001104659-26-027052.txt   8499154

Data Files

Seq Description Document Type Size
21 EX-101.SCH acxp-20251231.xsd EX-101.SCH 44806
22 EX-101.CAL acxp-20251231_cal.xml EX-101.CAL 28461
23 EX-101.DEF acxp-20251231_def.xml EX-101.DEF 147051
24 EX-101.LAB acxp-20251231_lab.xml EX-101.LAB 385956
25 EX-101.PRE acxp-20251231_pre.xml EX-101.PRE 272405
77 EXTRACTED XBRL INSTANCE DOCUMENT acxp-20251231x10k_htm.xml XML 772248
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40536 | Film No.: 26747651
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)